---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-066410"
form_type: "8-K"
ticker: "NAMS"
cik: "0001936258"
company_name: "NewAmsterdam Pharma Co N.V."
filed_at: "2025-05-08T23:59:59+00:00"
generated_at: "2026-05-22T05:42:37.203509+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# NewAmsterdam Pharma reports Q1 net loss $39.5M; cash $808.5M; EMA submission on track for 2H25

## Summary
- Cash $808.5M at Mar 31, 2025, down from $834.2M at Dec 31, 2024.
- Net loss $39.5M vs $93.8M YoY; revenue $3.0M vs $1.4M.
- EMA submission expected 2H25 by partner Menarini; PREVAIL CVOT enrollment completed.
- Adele Gulfo appointed to Board of Directors in April 2025.
- R&D expenses $44.8M; SG&A $27.2M, up due to commercial launch prep.

## SEC filing metadata
- accession: 0000950170-25-066410
- form_type: 8-K
- ticker: NAMS
- cik: 0001936258
- company_name: NewAmsterdam Pharma Co N.V.
- filed_at: 2025-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1936258/000095017025066410/0000950170-25-066410-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1936258/000095017025066410/nams-20250508.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-066410
- JSON: https://secwatch.observer/filing/0000950170-25-066410.json
- Plain text: https://secwatch.observer/filing/0000950170-25-066410.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.